Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin
|ClinicalTrials.gov Identifier: NCT01139320|
Recruitment Status : Completed
First Posted : June 8, 2010
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of DNA from patients receiving gemtuzumab ozogamicin may help doctors learn more about the effects of gemtuzumab ozogamicin on cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers in DNA samples from younger patients with newly diagnosed with acute myeloid leukemia receiving gemtuzumab ozogamicin.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: DNA analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis Other: pharmacological study|
- To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on COG-AAML03P1.
- To determine the association between these polymorphisms and clinical response of patients treated with this regimen.
OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based sequencing.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Pharmacogenetics of Mylotarg|
|Study Start Date :||September 2009|
|Primary Completion Date :||May 2016|
- Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139320
|Principal Investigator:||Jatinder Lamba, MD||Masonic Cancer Center, University of Minnesota|